Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Hassaan Imtiaz, Maimoona Khan, Hamid Ehsan, Ahsan Wahab, Abdul Rafae, Ali Y Khan, Abdur Jamil, Muhammad Khawar Sana, Abdullah Jamal, Taimoor Jaffar Ali, Iqraa Ansar, Muzammil M Khan, Jack Khouri & Faiz Anwer. (2021) Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. OncoTargets and Therapy 14, pages 4941-4960.
Read now
Read now
Articles from other publishers (18)
Felix I. L. Clanchy, Yi-Shu Huang, Joy Ogbechi, L. Gail Darlington, Richard O. Williams & Trevor W. Stone. (2022) Induction of IDO1 and Kynurenine by Serine Proteases Subtilisin, Prostate Specific Antigen, CD26 and HtrA: A New Form of Immunosuppression?. Frontiers in Immunology 13.
Crossref
Crossref
Vanessa Desantis, Aurelia Lamanuzzi, Ilaria Saltarella, Maria Antonia Frassanito, Angelo Vacca, Monica Montagnani & Domenico Ribatti. 2022. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
111
125
.
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
535
592
.
Panagiotis Efentakis, Garyfalia Psarakou, Aimilia Varela, Eleni Dimitra Papanagnou, Michail Chatzistefanou, Panagiota-Efstathia Nikolaou, Costantinos H. Davos, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios Athanasios Dimopoulos, Ioanna Andreadou & Evangelos Terpos. (2021) Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. International Journal of Molecular Sciences 22:20, pages 10956.
Crossref
Crossref
Katja Weisel, Maria-Victoria Mateos, Francesca Gay, Michel Delforge, Gordon Cook, Zsolt Szabo, Renaud Desgraz, Lucy DeCosta & Philippe Moreau. (2020) Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia 35:6, pages 1732-1744.
Crossref
Crossref
Coralia Cotoraci, Alina Ciceu, Alciona Sasu, Eftimie Miutescu & Anca Hermenean. (2021) Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma. Applied Sciences 11:10, pages 4451.
Crossref
Crossref
Efstathios Kastritis, Ageliki Laina, Georgios Georgiopoulos, Maria Gavriatopoulou, Eleni-Dimitra Papanagnou, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Nikolaos Kanellias, Ioanna Dialoupi, Nikolaos Makris, Efstathios Manios, Magdalini Migkou, Maria Roussou, Maria Kotsopoulou, Konstantinos Stellos, Evangelos Terpos, Ioannis P. Trougakos, Kimon Stamatelopoulos & Meletios A. Dimopoulos. (2021) Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia 35:5, pages 1418-1427.
Crossref
Crossref
Sara Ovejero & Jerome Moreaux. (2021) Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Khalid El Bairi, Dario Trapani, Angelica Petrillo, Cécile Le Page, Hanaa Zbakh, Bruno Daniele, Rhizlane Belbaraka, Giuseppe Curigliano & Said Afqir. (2020) Repurposing anticancer drugs for the management of COVID-19. European Journal of Cancer 141, pages 40-61.
Crossref
Crossref
Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D. Cohen, Eric M. Rohren, Stephen Heitner, Kevin Kelly, Niklas J. Mackler, David M. Baer, Antje Hoering, Brian Durie & Robert Z. Orlowski. (2020) Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clinical Cancer Research 26:15, pages 3969-3978.
Crossref
Crossref
Ying Chen, Rui Li, Yuqi Zhu, Sixia Zhong, Jinjun Qian, Dongqing Yang, Artur Jurczyszyn, Meral Beksac, Chunyan Gu & Ye Yang. (2020) Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. Frontiers in Oncology 10.
Crossref
Crossref
Meletios A. Dimopoulos, Ruben Niesvizky, Katja Weisel, David S. Siegel, Roman Hajek, María-Victoria Mateos, Michele Cavo, Mei Huang, Anita Zahlten-Kumeli & Philippe Moreau. (2020) Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood Cancer Journal 10:3.
Crossref
Crossref
Andrew J. Thorley, Simon Krautwald & David J. Rowlands. 2020. Anti-fibrotic Drug Discovery. Anti-fibrotic Drug Discovery
165
184
.
Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim S. Iskander, Khalid Mezzi & David S. Siegel. (2019) Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia 33:9, pages 2127-2143.
Crossref
Crossref
Panagiotis EfentakisGeorgios KremastiotisAimilia VarelaPanagiota-Efstathia NikolaouEleni-Dimitra PapanagnouConstantinos H. DavosMaria TsoumaniGeorgios Agrogiannis, Anastasia Konstantinidou, Efstathios KastritisZoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A. DimopoulosIoannis P. TrougakosIoanna Andreadou & Evangelos Terpos. (2019) Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood 133:7, pages 710-723.
Crossref
Crossref
Derek L.L. Hung, Susanna K.P. Lau & Patrick C.Y. Woo. (2019) Severe Sepsis Caused by Listeria monocytogenes in A Patient Given Monoclonal Antibodies Against CD38 and Proteosome Inhibitor. Infectious Microbes and Diseases 1:1, pages 30-31.
Crossref
Crossref
Domenico Ribatti & Angelo Vacca. (2018) New Insights in Anti-Angiogenesis in Multiple Myeloma. International Journal of Molecular Sciences 19:7, pages 2031.
Crossref
Crossref
Mariah L. Farrell & Michaela R. Reagan. (2018) Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma. Frontiers in Endocrinology 9.
Crossref
Crossref